Follow the Rapport Therapeutics, Inc. stock price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the authority of SEC (Form 4). Market capitalisation: €2.3bn. The latest transaction was filed on 9 September 2026 (Cession). Among the most active insiders: Ceesay Abraham. All data is openly available.
65
Insider Decl.
n/a
Thresholds
€1m
6 ops.
Buy Volume
€25m
46 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Rapport Therapeutics, Inc. Strong Buy (bullish), based on 12 analysts. Average price target: US$62.05.
48Σ signal
Buys €1m€25m Sells
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
426,005 shares@ US$40.3170.88% mcap100.0% of flowCommon StockSEC:0001193125-26-167636:0
25 of 65 declarations
Acerca de Rapport Therapeutics, Inc.
Rapport Therapeutics, Inc. es una empresa centrada en el desarrollo de tratamientos innovadores para enfermedades neurológicas. Cotiza en el mercado XNAS.